Cerebral salt-wasting syndrome in a patient with neuroleptic malignant syndrome

Archives of Neurology

Volumn 64, Issue 1, 2007, Pages 122-125

  Lenhard, Thorsten ^a   Külkens, Sonja ^a   Schwab, Stefan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DANTROLENE; HALOPERIDOL DECANOATE; OLANZAPINE; SODIUM; VASOPRESSIN;

ADULT; ARTICLE; BLOOD TOXICITY; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; FLUID THERAPY; HUMAN; HYPONATREMIA; LABORATORY TEST; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PHYSICAL EXAMINATION; PLASMA OSMOLALITY; POLYURIA; PRIORITY JOURNAL; PSYCHOSIS; RHABDOMYOLYSIS; SALT LOSING NEPHRITIS; SEROLOGY; SODIUM BLOOD LEVEL; SODIUM EXCRETION; SOPOR; TACHYCARDIA;

CREATINE KINASE; DANTROLENE; FEMALE; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; MIDDLE AGED; MYOGLOBINURIA; NEUROLEPTIC MALIGNANT SYNDROME; SODIUM;

EID: 33846040671     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.1.122     Document Type: Article

References (12)

1. Rabinstein AA, Wijdicks EFM. Hyponatremia in critically ill neurological patients. Neurologist. 2003;9:290-300.
2. Maesaka JK, Gupta S, Fishbane S. Cerebral salt-wasting syndrome. Nephron. 1999;82:100-109.
3. Grebb JA. Medication-induced movement disorders. In: Sadock BJ, Sadock VA, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2004:1909-1915.
4. Farver DK. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf. 2003;2:21-35.
5. Oh MS, Carroll HJ. Cerebral salt-wasting syndrome: we need better proof of its existence. Nephron. 1999;82:110-114.
6. Saper CB, Hurley KM, Moga MM, et al. Brain natriuretic peptides: differential localization of a new family of neuropeptides. Neurosci Lett. 1989;96:29-34.
7. Lee YJ, Lin SR, Shin SJ, Lai YH, Lin YT, Tsai JH. Brain natriuretic peptide is synthesized in the human adrenal medulla and its messenger ribonucleic acid expression along with that of atrial natriuretic peptide are enhanced in patients with primary aldosteronism. J Clin Endocrinol Metab. 1994;79:1476-1482.
8. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999;156:169-180.
9. Israel A, Torres M, Barbella Y. Evidence for a dopaminergic mechanism for the diuretic and natriuretic action of centrally administered atrial natriuretic factor. Cell Mol Neurobiol. 1989;9:369-378.
10. Hansell P, Sjöquist M, Fasching A, Isaksson B, Karlson M, Ulfendahl HR. CNS induced natriuresis during dopamine receptor blockade: further support for the existence of at least two separate natriuretic hormonal systems. Acta Physiol Scand. 1988;133:373-380.
11. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene: a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59:364-373.
12. Nozaki H, Tanaka K, Gomi S, et al. Role of the ryanodine receptor in ischemic brain damage: localized reduction of ryanodine receptor binding during ischemia in hippocampus CA1. Cell Mol Neurobiol. 1999;19:119-131.